[Effect of actarit combination therapy in patients with active rheumatoid arthritis resistant to gold agents].
We investigated the utility of combination therapy of actarit with gold agents in patients with active rheumatoid arthritis resistant to gold agents even after the administration of gold agents for longer than 24 weeks in principle. 1. In the final global improvement rate by the combination therapy of actarit with gold agents, the ratio of "improved" and/or better was 30.8% (12/39). 2. The clinical evaluation items which showed significant improvement were grip strength, ESR, number of painful joints, number of swollen joints, active joint count, duration of morning stiffness and Lansbury's activity index. 3. ADRs were observed in 6 patients per 75 patients (8.0%), but there was no serious ADR.
Sakurai
T
T
Department of Orthopedic Surgery, Maebashi Red Cross Hospital, Maebashi-city.
Iso
T
T
Inoue
H
H
Sano
K
K
Takeuchi
K
K
Takagishi
K
K
D000368:Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000503:physiopathology; D001310:Auranofin / Q000627:therapeutic use*; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010648:Phenylacetates / Q000627:therapeutic use*; D016896:Treatment Outcome
D018501:Antirheumatic Agents; D010648:Phenylacetates; C052562:4-(acetylamino)benzeneacetic acid; D001310:Auranofin